DOCSLIB.ORG

Global Strategy for Asthma Management and Prevention, 2019. Available From

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Global Strategy for Asthma Management and Prevention, 2019. Available From DISTRIBUTE OR COPY NOT DO MATERIAL- COPYRIGHTED ASTHMA MANAGEMENT AND PREVENTION GLOBAL STRATEGY FOR Updated 2019 9 Global Strategy for Asthma Management and Prevention (2019 update) DISTRIBUTE OR COPY NOT DO The reader acknowledges that this reportMATERIAL- is intended as an evidence-based asthma management strategy, for the use of health professionals and policy-makers. It is based, to the best of our knowledge, on current best evidence and medical knowledge and practice at the date of publication. When assessing and treating patients, health professionals are strongly advised to use their own professional judgment, and to take into account local or national regulations and guidelines. GINA cannot be held liable or responsible for inappropriate healthcare associated with the use of this document, including any use which is not in accordance with applicable local or national regulations or COPYRIGHTEDguidelines. This document should be cited as: Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2019. Available from: www.ginasthma.org 1 Table of contents Tables and figures ............................................................................................................................................................... 5 Preface ................................................................................................................................................................................. 7 Members of GINA committees (2018) ................................................................................................................................. 8 Methodology......................................................................................................................................................................... 9 What’s new in GINA 2019? ................................................................................................................................................ 12 Peer-reviewed publications about the GINA report ........................................................................................................... 14 SECTION 1. ADULTS, ADOLESCENTS AND CHILDREN 6 YEARS AND OLDER ........................................................ 15 Chapter 1. Definition, description, and diagnosis of asthma ........................................................................................... 15 Definition of asthma ................................................................................................................................................... 16 Description of asthma ................................................................................................................................................ 16 Making the initial diagnosis ........................................................................................................................................ 17 Confirming the diagnosis of asthma in patients already taking controller treatment ................................................. 22 DISTRIBUTE Differential diagnosis .................................................................................................................................................. 24 OR How to make the diagnosis of asthma in other contexts ........................................................................................... 25 Chapter 2. Assessment of asthma ................................................................................................COPY .................................... 27 Overview .................................................................................................................................................................... 28 NOT Assessing asthma symptom control .......................................................................................................................... 29 DO Assessing future risk of adverse outcomes ............................................................................................................... 33 Role of lung function in assessing asthma control..................................................................................................... 33 Assessing asthma severity ........................................................................................................................................ 35 Chapter 3. Treating asthma to control symptomsMATERIAL- and minimize risk ................................................................................ 37 Part A. General principles of asthma management ....................................................................................................... 38 Long-term goals of asthma management .................................................................................................................. 38 The patient-health care provider partnership ............................................................................................................. 39 Control-based asthma COPYRIGHTEDmanagement.......................................................................................................................... 40 Part B. Medications and strategies for symptom control and risk reduction .................................................................. 43 Asthma medications ................................................................................................................................................... 44 Reviewing response and adjusting treatment ............................................................................................................ 54 Treating other modifiable risk factors ......................................................................................................................... 57 Other therapies .......................................................................................................................................................... 58 Non-pharmacological strategies ................................................................................................................................ 60 Indications for referral for expert advice .................................................................................................................... 68 Part C. Guided asthma self-management education and skills training ........................................................................ 69 Overview .................................................................................................................................................................... 69 Skills training for effective use of inhaler devices ...................................................................................................... 69 2 Adherence with medications and other advice .......................................................................................................... 70 Asthma information .................................................................................................................................................... 72 Training in guided asthma self-management ............................................................................................................ 73 Part D. Managing asthma with comorbidities and in specific populations ..................................................................... 75 Managing comorbidities ............................................................................................................................................. 75 Managing asthma in specific populations or settings ................................................................................................ 78 Part E. Difficult-to-treat and severe asthma in adults and adolescents ......................................................................... 84 Definitions: uncontrolled, difficult-to-treat and severe asthma ................................................................................... 84 Prevalence: how many people have severe asthma? ............................................................................................... 85 Importance: the impact of severe asthma ................................................................................................................. 85 Investigate and manage adult and adolescent patients with difficult-to-treat asthma ............................................... 91 Assess and treat severe asthma phenotypes ............................................................................................................ 93 Manage and monitor severe asthma treatment ......................................................................................................... 98 Chapter 4. Management of worsening asthma and exacerbations ................................................................................DISTRIBUTE 101 Overview ................................................................................................OR.................................................................. 103 Diagnosis of exacerbations ...................................................................................................................................... 104 COPY Self-management of exacerbations with a written asthma action plan ................................................................... 104 Management of asthma exacerbations in primary care...........................................................................................NOT 108 Management
Load more

Recommended publications
  • “Bicentennial Speeches (2)” of the Ron Nessen Papers at the Gerald R
    The original documents are located in Box 2, folder “Bicentennial Speeches (2)” of the Ron Nessen Papers at the Gerald R. Ford Presidential Library. Copyright Notice The copyright law of the United States (Title 17, United States Code) governs the making of photocopies or other reproductions of copyrighted material. Ron Nessen donated to the United States of America his copyrights in all of his unpublished writings in National Archives collections. Works prepared by U.S. Government employees as part of their official duties are in the public domain. The copyrights to materials written by other individuals or organizations are presumed to remain with them. If you think any of the information displayed in the PDF is subject to a valid copyright claim, please contact the Gerald R. Ford Presidential Library. Digitized from Box 2 of The Ron Nessen Papers at the Gerald R. Ford Presidential Library THE WHITE HOUSE WASHINGTON June 28, 1976 MEMORANDUM FOR ROBERT ORBEN VIA: GWEN ANDERSON FROM: CHARLES MC CALL SUBJECT: PRE-ADVANCE REPORT ON THE PRESIDENT'S ADDRESS AT THE NATIONAL ARCHIVES Attached is some background information regarding the speech the President will make on July 2, 1976 at the National Archives. ***************************************************************** TAB A The Event and the Site TAB B Statement by President Truman dedicating the Shrine for the Delcaration, Constitution, and Bill of Rights, December 15, 1952. r' / ' ' ' • THE WHITE HOUSE WASHINGTON June 28, 1976 MEMORANDUM FOR BOB ORBEN VIA: GWEN ANDERSON FROM: CHARLES MC CALL SUBJECT: NATIONAL ARCHIVES ADDENDUM Since the pre-advance visit to the National Archives, the arrangements have been changed so that the principal speakers will make their addresses inside the building .
    [Show full text]
  • Section 8 Pulmonary Medicine
    SECTION 8 PULMONARY MEDICINE 336425_ST08_286-311.indd6425_ST08_286-311.indd 228686 111/7/121/7/12 111:411:41 AAMM CHAPTER 66 EVALUATION OF CHRONIC COUGH 1. EPIDEMIOLOGY • Nearly all adult cases of chronic cough in nonsmokers who are not taking an ACEI can be attributed to the “Pathologic Triad of Chronic Cough” (asthma, GERD, upper airway cough syndrome [UACS; previously known as postnasal drip syndrome]). • ACEI cough is idiosyncratic, occurrence is higher in female than males 2. PATHOPHYSIOLOGY • Afferent (sensory) limb: chemical or mechanical stimulation of receptors on pharynx, larynx, airways, external auditory meatus, esophagus stimulates vagus and superior laryngeal nerves • Receptors upregulated in chronic cough • CNS: cough center in nucleus tractus solitarius • Efferent (motor) limb: expiratory and bronchial muscle contraction against adducted vocal cords increases positive intrathoracic pressure 3. DEFINITION • Subacute cough lasts between 3 and 8 weeks • Chronic cough duration is at least 8 weeks 4. DIFFERENTIAL DIAGNOSIS • Respiratory tract infection (viral or bacterial) • Asthma • Upper airway cough syndrome (postnasal drip syndrome) • CHF • Pertussis • COPD • GERD • Bronchiectasis • Eosinophilic bronchitis • Pulmonary tuberculosis • Interstitial lung disease • Bronchogenic carcinoma • Medication-induced cough 5. EVALUATION AND TREATMENT OF THE COMMON CAUSES OF CHRONIC COUGH • Upper airway cough syndrome: rhinitis, sinusitis, or postnasal drip syndrome • Presentation: symptoms of rhinitis, frequent throat clearing, itchy
    [Show full text]
  • Pharmacotherapeutic Considerations for Individuals with Down Syndrome Erik Hefti
    Harrisburg University of Science and Technology Digital Commons at Harrisburg University Harrisburg University Faculty Works 12-8-2016 Pharmacotherapeutic Considerations for Individuals with Down Syndrome Erik Hefti Follow this and additional works at: http://digitalcommons.harrisburgu.edu/faculty-works Part of the Congenital, Hereditary, and Neonatal Diseases and Abnormalities Commons, and the Medicinal and Pharmaceutical Chemistry Commons R EVIEW O F T HERAPEUTICS Pharmacotherapeutic Considerations for Individuals with Down Syndrome Erik Hefti,* and Javier G. Blanco* Department of Pharmaceutical Sciences, The School of Pharmacy and Pharmaceutical Sciences, The State University of New York at Buffalo, Buffalo, New York Down syndrome (DS; trisomy 21) is the most common survivable disorder due to aneuploidy. Individ- uals with DS may experience multiple comorbid health problems including congenital heart defects, endocrine abnormalities, skin and dental problems, seizure disorders, leukemia, dementia, and obesity. These associated conditions may necessitate pharmacotherapeutic management with various drugs. The complex pathobiology of DS may alter drug disposition and drug response in some individuals. For example, reports have documented increased rates of adverse drug reactions in patients with DS treated for leukemia and dementia. Intellectual disability resulting from DS may impact adherence to medication regimens. In this review, we highlight literature focused on pharmacotherapy for individu- als with DS. We discuss reports of altered drug disposition or response in patients with DS and explore social factors that may impact medication adherence in the DS setting. Enhanced monitoring during drug therapy in individuals with DS is justified based on reports of altered drug disposition, drug response, and other characteristics present in this population.
    [Show full text]
  • Respiratory Syncytial Virus Bronchiolitis in Children DUSTIN K
    Respiratory Syncytial Virus Bronchiolitis in Children DUSTIN K. SMITH, DO; SAJEEWANE SEALES, MD, MPH; and CAROL BUDZIK, MD Naval Hospital Jacksonville, Jacksonville, Florida Bronchiolitis is a common lower respiratory tract infection in infants and young children, and respiratory syncytial virus (RSV) is the most common cause of this infection. RSV is transmitted through contact with respiratory droplets either directly from an infected person or self-inoculation by contaminated secretions on surfaces. Patients with RSV bronchiolitis usually present with two to four days of upper respiratory tract symptoms such as fever, rhinorrhea, and congestion, followed by lower respiratory tract symptoms such as increasing cough, wheezing, and increased respira- tory effort. In 2014, the American Academy of Pediatrics updated its clinical practice guideline for diagnosis and man- agement of RSV bronchiolitis to minimize unnecessary diagnostic testing and interventions. Bronchiolitis remains a clinical diagnosis, and diagnostic testing is not routinely recommended. Treatment of RSV infection is mainly sup- portive, and modalities such as bronchodilators, epinephrine, corticosteroids, hypertonic saline, and antibiotics are generally not useful. Evidence supports using supplemental oxygen to maintain adequate oxygen saturation; however, continuous pulse oximetry is no longer required. The other mainstay of therapy is intravenous or nasogastric admin- istration of fluids for infants who cannot maintain their hydration status with oral fluid intake. Educating parents on reducing the risk of infection is one of the most important things a physician can do to help prevent RSV infection, especially early in life. Children at risk of severe lower respiratory tract infection should receive immunoprophy- laxis with palivizumab, a humanized monoclonal antibody, in up to five monthly doses.
    [Show full text]
  • Allergic Bronchopulmonary Aspergillosis As a Cause of Bronchial Asthma in Children
    Egypt J Pediatr Allergy Immunol 2012;10(2):95-100. Original article Allergic bronchopulmonary aspergillosis as a cause of bronchial asthma in children Background: Allergic bronchopulmonary aspergillosis (ABPA) occurs in Dina Shokry, patients with asthma and cystic fibrosis. When aspergillus fumigatus spores Ashgan A. are inhaled they grow in bronchial mucous as hyphae. It occurs in non Alghobashy, immunocompromised patients and belongs to the hypersensitivity disorders Heba H. Gawish*, induced by Aspergillus. Objective: To diagnose cases of allergic bronchopulmonary aspergillosis among asthmatic children and define the Manal M. El-Gerby* association between the clinical and laboratory findings of aspergillus fumigatus (AF) and bronchial asthma. Methods: Eighty asthmatic children were recruited in this study and divided into 50 atopic and 30 non-atopic Departments of children. The following were done: skin prick test for aspergillus fumigatus Pediatrics and and other allergens, measurement of serum total IgE, specific serum Clinical Pathology*, aspergillus fumigatus antibody titer IgG and IgE (AF specific IgG and IgE) Faculty of Medicine, and absolute eosinophilic count. Results: ABPA occurred only in atopic Zagazig University, asthmatics, it was more prevalent with decreased forced expiratory volume Egypt. at the first second (FEV1). Prolonged duration of asthma and steroid dependency were associated with ABPA. AF specific IgE and IgG were higher in the atopic group, they were higher in Aspergillus fumigatus skin Correspondence: prick test positive children than negative ones .Wheal diameter of skin prick Dina Shokry, test had a significant relation to the level of AF IgE titer. Skin prick test Department of positive cases for aspergillus fumigatus was observed in 32% of atopic Pediatrics, Faculty of asthmatic children.
    [Show full text]
  • Occupational Safety
    OCCUPATIONAL SAFETY AND HEALTH STANDARDS PART 7 Longshoring HAWAII ADMINISTRATIVE RULES TITLE 12 DEPARTMENT OF LABOR AND INDUSTRIAL RELATIONS SUBTITLE 8 DIVISION OF OCCUPATIONAL SAFETY AND HEALTH PART 7 OCCUPATIONAL SAFETY AND HEALTH STANDARDS FOR LONGSHORING Chapter 12-190 Longshoring This unofficial copy varies from the administrative rules format in that all sections follow directly after the previous section; small letters designating subsections are in bold type; page numbers have been added to the bottom center of each page; headers do not include the section number, only the title and chapter number; and sections that incorporate federal (Department of Labor, Occupational Safety and Health Administration) standards through reference include the federal standard. These variations facilitate changes to and use of the HIOSH rules and standards. This is an official copy in all other respects. HAWAII ADMINISTRATIVE RULES §12-190 TITLE 12 DEPARTMENT OF LABOR AND INDUSTRIAL RELATIONS SUBTITLE 8 DIVISION OF OCCUPATIONAL SAFETY AND HEALTH PART 7 SAFETY AND HEALTH REGULATIONS FOR LONGSHORING CHAPTER 190 LONGSHORING §12-190-1 Incorporation of federal standard §12-190-1 Incorporation of federal standard. Title 29, Code of Federal Regulations. Part 1918 entitled “Safety and Health Regulations for Longshoring”, published by the Office of the Federal Register, National Archives and Records Administration, on July 9, 1974; and the amendments published on July 22, 1977; August 24, 1987; February 9, 1994; July 19, 1994; December 22, 1994; February 13, 1996; July 25, 1997; December 1, 1998; August 27, 1999; November 12, 1999; June 30, 2000; and February 28, 2006, are made part of this chapter.
    [Show full text]
  • New Spirometry Interpretation Algorithm Primary Care Respiratory Alliance of Canada Approach
    Critical Appraisal New spirometry interpretation algorithm Primary Care Respiratory Alliance of Canada approach Anthony D. D’Urzo MD MSc CCFP FCFP Itamar Tamari MD CCFP FCFP Jacques Bouchard MD Reuven Jhirad MD CCFP FCFP Pieter Jugovic MD MSc CCFP Clinical question Is there a need for a new spirometry interpretation algorithm that contains decision-making criteria consistent with current guidelines on asthma1 and chronic obstructive pulmonary disease (COPD)2 diagnosis? Using spirometry to distinguish between COPD and asthma Office spirometry provides valuable information about the relationship between flow and volume in relation to lung function and can be useful for diagnosing common conditions such as asthma and COPD.1,2 Mechanical abnor- malities of the respiratory system can be classified as either obstructive (flow-related) or restrictive (volume-related) ventilatory defects; obstructive defects are much more common in clinical practice. The relationship between flow and volume is described well by BOTTOM LINE • An algorithm commonly promoted in the ratio of the forced expiratory volume in 1 second (FEV1) to the forced vital capacity (FVC). These measurements can be easily obtained with a primary care is limited by its focus on using simple office spirometer during a forced expiratory maneuver. The ratio changes in forced expiratory volume in 1 second (FEV ) to distinguish asthma from of FEV1 to FVC can be useful to identify obstructive, restrictive, and com- 1 bined (obstructive-restrictive) defects, but it is important to recognize that chronic obstructive pulmonary disease total lung capacity, a more sophisticated measurement (and not the FVC), (COPD). The new algorithm consolidates is the best measurement to confirm a diagnosis of pulmonary restriction.3 current spirometric concepts that are consistent with both asthma and COPD Traditionally an FEV1-FVC ratio below 0.70 has been used to define a pure obstructive defect if the FVC is within normal limits.
    [Show full text]
  • Understanding Asthma
    Understanding Asthma The Mount Sinai − National Jewish Health Respiratory Institute was formed by the nation’s leading respiratory hospital National Jewish Health, based in Denver, and top ranked academic medical center the Icahn School of Medicine at Mount Sinai in New York City. Combining the strengths of both organizations into an integrated Respiratory Institute brings together leading expertise in diagnosing and treating all forms of respiratory illness and lung disease, including asthma, chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD) and bronchiectasis. The Respiratory Institute is based in New York City on the campus of Mount Sinai. njhealth.org Understanding Asthma An educational health series from National Jewish Health IN THIS ISSUE What Is Asthma? 2 How Does Asthma Develop? 4 How Is Asthma Diagnosed? 5 What Are the Goals of Treatment? 7 How Is Asthma Managed? 7 What Things Make Asthma Worse and How Can You Control Them? 8 Nocturnal Asthma 18 Occupational Asthma 19 Medication Therapy 20 Monitoring Your Asthma 29 Using an Action Plan 33 Living with Asthma 34 Note: This information is provided to you as an educational service of National Jewish Health. It is not meant as a substitute for your own doctor. © Copyright 1998, revised 2014, 2018 National Jewish Health What Is Asthma? This booklet, prepared by National Jewish Health in Denver, is intended to provide information to people with asthma. Asthma is a chronic respiratory disease — sometimes worrisome and inconvenient — but a manageable condition. With proper understanding, good medical care and monitoring, you can keep asthma well controlled. That’s our treatment goal at National Jewish Health: to teach patients and families how to manage asthma, so that they can lead full and productive lives.
    [Show full text]
  • Intranasal Ipratropium Bromide Reduced Rhinorrhea and Improved Cold Symptoms
    /:*-..= S Evid Based Med: first published as 10.1136/ebm.1996.1.205 on 1 December 1996. Downloaded from Intranasal ipratropium bromide reduced rhinorrhea and improved cold symptoms Hayden FG, Diamond L, Wood PB, 0.06% in a buffered salt solution (P = 0.003). {This 17% absolute dif- KortsDC, Wecker MT. Effectiveness (2 sprays/nostril [84 u,g] 3 times/d ference in improvement between the and safety of intranasal ipratropium for 4 d) (n = 137), the same nasal ipratropium and placebo groups bromide in common colds. A ran- spray without ipratropium in = 137), means that 6 patients (95% CI, 4 to domized, double-blind, placebo- or no medication (n = 137). No cold 16) would need to be treated with controlled trial. Ann Intern Med. medications other than analgesics ipratropium (rather than placebo) for 1996JullS;12S:89-91. and antitussives were allowed. 4 days to result in improvement for 1 additional patient; the relative risk Main outcome measures improvement was 26%, CI 9% to Objective 47%* }. Rates of nasal dryness (12% To determine whether intxanasal ipra- The main outcome measure was a vs 4%), blood-tinged mucus (17% vs tropium bromide is effective and safe global assessment of overall improve- 4%), and headache (9% vs 2%) were for reducing common cold symptoms. ment (report by patients of being better or much better). Rhinorrhea greater in the ipratropium group than Design was monitored in the clinic hourly in the placebo group. 6-day, randomized, double-blind, for the first 6 hours on day 1 and Conclusion placebo-controlled trial. hourly for 3 hours on day 2.
    [Show full text]
  • Asthma Exacerbation Management
    CLINICAL PATHWAY ASTHMA EXACERBATION MANAGEMENT TABLE OF CONTENTS Figure 1. Algorithm for Asthma Exacerbation Management – Outpatient Clinic Figure 2. Algorithm for Asthma Management – Emergency Department Figure 3. Algorithm for Asthma Management – Inpatient Figure 4. Progression through the Bronchodilator Weaning Protocol Table 1. Pediatric Asthma Severity (PAS) Score Table 2. Bronchodilator Weaning Protocol Target Population Clinical Management Clinical Assessment Treatment Clinical Care Guidelines for Treatment of Asthma Exacerbations Children’s Hospital Colorado High Risk Asthma Program Table 3. Dosage of Daily Controller Medication for Asthma Control Table 4. Dosage of Medications for Asthma Exacerbations Table 5. Dexamethasone Dosing Guide for Asthma Figure 5. Algorithm for Dexamethasone Dosing – Inpatient Asthma Patient | Caregiver Education Materials Appendix A. Asthma Management – Outpatient Appendix B. Asthma Stepwise Approach (aka STEPs) Appendix C. Asthma Education Handout References Clinical Improvement Team Page 1 of 24 CLINICAL PATHWAY FIGURE 1. ALGORITHM FOR ASTHMA EXACERBATION MANAGEMENT – OUTPATIENT CLINIC Triage RN/MA: • Check HR, RR, temp, pulse ox. Triage level as appropriate • Notify attending physician if patient in severe distress (RR greater than 35, oxygen saturation less than 90%, speaks in single words/trouble breathing at rest) Primary RN: • Give oxygen to keep pulse oximetry greater than 90% Treatment Inclusion Criteria 1. Give nebulized or MDI3 albuterol up to 3 doses. Albuterol dosing is 0.15 to 0.3mg/kg per 2007 • 2 years or older NHLBI guidelines. • Treated for asthma or asthma • Less than 20 kg: 2.5 mg neb x 3 or 2 to 4 puffs MDI albuterol x 3 exacerbation • 20 kg or greater: 5 mg neb x 3 or 4 to 8 puffs MDI albuterol x 3 • First time wheeze with history consistent Note: For moderate (dyspnea interferes with activities)/severe (dyspnea at rest) exacerbations you with asthma can add atrovent to nebulized albuterol at 0.5mg/neb x 3.
    [Show full text]
  • DEMAND REDUCTION a Glossary of Terms
    UNITED NATIONS PUBLICATION Sales No. E.00.XI.9 ISBN: 92-1-148129-5 ACKNOWLEDGEMENTS This document was prepared by the: United Nations International Drug Control Programme (UNDCP), Vienna, Austria, in consultation with the Commonwealth of Health and Aged Care, Australia, and the informal international reference group. ii Contents Page Foreword . xi Demand reduction: A glossary of terms . 1 Abstinence . 1 Abuse . 1 Abuse liability . 2 Action research . 2 Addiction, addict . 2 Administration (method of) . 3 Adverse drug reaction . 4 Advice services . 4 Advocacy . 4 Agonist . 4 AIDS . 5 Al-Anon . 5 Alcohol . 5 Alcoholics Anonymous (AA) . 6 Alternatives to drug use . 6 Amfetamine . 6 Amotivational syndrome . 6 Amphetamine . 6 Amyl nitrate . 8 Analgesic . 8 iii Page Antagonist . 8 Anti-anxiety drug . 8 Antidepressant . 8 Backloading . 9 Bad trip . 9 Barbiturate . 9 Benzodiazepine . 10 Blood-borne virus . 10 Brief intervention . 11 Buprenorphine . 11 Caffeine . 12 Cannabis . 12 Chasing . 13 Cocaine . 13 Coca leaves . 14 Coca paste . 14 Cold turkey . 14 Community empowerment . 15 Co-morbidity . 15 Comprehensive Multidisciplinary Outline of Future Activities in Drug Abuse Control (CMO) . 15 Controlled substance . 15 Counselling and psychotherapy . 16 Court diversion . 16 Crash . 16 Cross-dependence . 17 Cross-tolerance . 17 Custody diversion . 17 Dance drug . 18 Decriminalization or depenalization . 18 Demand . 18 iv Page Demand reduction . 19 Dependence, dependence syndrome . 19 Dependence liability . 20 Depressant . 20 Designer drug . 20 Detoxification . 20 Diacetylmorphine/Diamorphine . 21 Diuretic . 21 Drug . 21 Drug abuse . 22 Drug abuse-related harm . 22 Drug abuse-related problem . 22 Drug policy . 23 Drug seeking . 23 Drug substitution . 23 Drug testing . 24 Drug use .
    [Show full text]
  • New Accessory Line up for Warn Winches and Warn Ploughs
    New Accessory Line up for Warn winches and Warn ploughs With the introduction of the Vantage and Provantage winches the line up of accessories were updated as well. These new accessories will make winching more easy and gives you a better handling while using the plough as well www.yamaha-motor.eu Propivot plough Rotates plough blade up to 28 degrees at the push of a button- even under load . P/N YME887000000 •Equipped with a powerful motor •designed using a durable split-ring gear train, ProPivot will make quick work of all ploughing activities. •Improved sealing along with a shock absorbing dampener system makes the ProPivot a must-have when you need superior response and versatile plough performance. Note; Propivot can not be lifted with Provantage plough lift (YMD846000000) Propivot system can only be lifted with winch. Supersession of the “old” power pivot YMD793600000 Neoprene Winch Cover Protects the winch from water and freezing P/N YME719800000 •Made of durable, tight-fitting neoprene that resists water and cracking Fit on; Vantage 3000 Pro-vantage 2500 and 3500 www.yamaha-motor.eu Wireless control kit Control your winch from anywhere within a 15 metre range of your vehicle. P/N YME902880000 • Let’s you operate your winch from anywhere within a 15 metre radius. • Two-colour LED provides instant feedback during the winching process. • System shuts off automatically after three minutes (or it can be turned off manually) to conserve battery life. The WARN® Wireless Control System will work with WARN 1.5ci, 2.5ci,3.0ci, RT/XT, Vantage and ProVantage winches Supersession of the “old” wireless control kit YMD745000000 Plough HD mounting Upgrade mounting points which increase the durability and performance of your system P/N YME852430000 • Wear-form steel construction.
    [Show full text]